Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Guardant Health has partnered with the Parker Institute for Cancer Immunotherapy (PICI) for a research collaboration to study cancer biomarkers and their correlation with immunotherapy responses. This project will analyze patient blood samples from PICI’s RADIOHEAD study, a prospective analysis involving 1,200 participants receiving immune checkpoint inhibitors.
The collaboration aims to enhance understanding of resistance to immune therapies across more than 14 cancer types. Guardant Health will utilize its GuardantINFINITY platform for a multi-dimensional assessment of tumor responses. The findings will contribute to real-world data on immunotherapy outcomes.
Data publication is expected later in 2023, marking a significant step in the development of personalized cancer treatments.
Guardant Health announced that its ECLIPSE Study data will be presented as a late-breaking abstract at Digestive Disease Week (DDW) from May 6-9, 2023, in Chicago. The study focuses on the performance of the Shield blood test for early-stage colorectal cancer detection in asymptomatic patients. Co-CEO AmirAli Talasaz emphasized the test's potential to increase screening rates, which remain low despite existing modalities. Gastroenterologist Daniel Chung also highlighted the need for less invasive screening methods. The acceptance of the ECLIPSE Study signifies a robust research effort, and further data will be shared during the conference. Guardant Health aims to improve adherence to cancer screening through its innovative technologies.